Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Orlistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP known ✓ | P16233 | 1/20 | 1.00 |
| ▸ | DAGLA | Q9Y4D2 | 8/20 | 1.00 |
| ▸ | CNR1 | P21554 | 5/20 | 1.00 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABHD16A | O95870 | 1/20 | 1.00 |
| ▸ | LPL | P06858 | 1/20 | 1.00 |
| ▸ | LIPC | P11150 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 1.00 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 1.00 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 1.00 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orlistat SCHEMBL608747 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4129379 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4129375 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL13210085 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL4132911 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL3270614 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL2473855 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| SCHEMBL12083554 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL22252870 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 | |
| Orlistat SCHEMBL10922890 | 1.00 | DAGLA (1.00) | DAGLACNR1DAGLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 42450 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638448-B2 | Compositions, methods, and kits for detection of lipolytic activity | LONZA LTD (CH) | 2026-05-26 | — | — | US | claimed |
| CN-122075465-A | Use of propionyl carnitine for improving obesity and insulin resistance | — | 2026-05-26 | — | — | CN | claimed |
| CN-121202992-B | Novel long-acting Amylin receptor agonist and application thereof | Hangzhou Nuo Ao Biopharmaceutical Technology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| CN-122032552-A | O rich in oxygen vacanciesV-Fe3O4Bamboo charcoal composite photocatalyst, and preparation method and application thereof | 浙江大学衢州研究院 | 2026-05-15 | — | — | CN | claimed |
| CN-122031677-A | Leptin receptor agonist antibodies for the treatment of metabolic dysfunction or hypoleptinemia | 瑞泽恩制药公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260128144-A1 | Systems and Methods for Pharmacotherapeutic Intervention in Obesity Treatment Targeting Multiple Neurophysiological Mechanisms Using Patient Phenotyping Modeling | INTELLIHEALTH INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-0803576-A2 | Process for the production of lipstatin and tetrahydrolipstatin | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-29 | — | — | EP | claimed |
| EP-0764017-A4 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMA INC (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0764017-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1997-03-26 | — | — | EP | claimed |
| US-5540917-A | Biomass lipase inhibitor useful for treating adiposity | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | claimed |
| CN-1106701-A | Pharmaceutical composition | HOFFMANN LA ROCHE (CH) | 1995-08-16 | — | — | CN | claimed |
| EP-0638317-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-15 | — | — | EP | claimed |
| WO-1994021230-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| EP-0575846-A2 | Food and feedstuff containing lipase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-29 | — | — | EP | claimed |
| EP-0129748-B1 | HEXADECANOIC ACID AND HEXADECADIENOIC-ACID DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-30 | — | — | EP | claimed |
| EP-0129748-A1 | Hexadecanoic acid and hexadecadienoic-acid derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-01-02 | — | — | EP | claimed |